NCT06010342招募中2 期
A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
Teligene US38 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2023年3月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 38
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
详细描述
TL118 is an orally active inhibitor of the tropomyosin receptor kinase (Trk) family consists of TrkA, TrkB, and TrkC. These receptors are encoded by the NTRK1, NTRK2 and NTRK3 genes, and oncogenic fusions of NTRK may cause cancer cells to grow and spread in the body. The purpose of this study is to explore how effective TL118 is for the treatment of patients with solid tumors harboring NTRK gene fusions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years old and above, male or female
- •Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3 gene fusion that is predicted to translate into a fusion protein with a functional tropomyosin receptor kinase (TRK)A/B/C kinase domain, without a concomitant second onco-driver
- •Patients must have had disease progression during or after prior treatment for their tumor, or would be unlikely to tolerate or derive clinical benefit from appropriate standard of care therapy or are not suitable - in the opinion of the Investigator - to receive standard of care therapy; prior treatment with approved or investigational TRK inhibitors is not allowed, except for prior TRK treatment for less than 28 days due to intolerable toxicity)
- •At least one measurable lesion
- •Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2
- •A minimum life expectancy of > 3 months
- •Adequate bone marrow reserve, hepatic, renal, and coagulation function
- •Other inclusion criteria apply for participating in the Study
排除标准
- •Any systemic anti-tumor therapy such as chemotherapy and radiation therapy (including curative radiotherapy or spinal radiotherapy portion > 30%) used within 3 weeks prior to enrollment; immunotherapy within 4 weeks; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines (TCMs) indicated for the tumor (including Chinese patent medicine) within 2 weeks prior to enrollment
- •Participation in another interventional clinical trial 2 weeks prior to enrollment or within 5 half-lives from the last dose of IP (whichever is shorter)
- •Any unresolved toxicities from prior therapy greater than Grade 1, at the time of screening with the exception of toxicities posing no safety risk in the opinion of the Investigator
- •Active central nervous system metastases
- •Any other primary malignant tumors within 3 years (except for cured skin basal cell carcinoma and carcinoma in situ of cervix, low-risk cancer
- •Any active infection which has not been controlled at screening
- •Other exclusion criteria apply for participating in the Study
研究组 & 干预措施
Single arm, Open label
Experimental
Participants will receive TL118 capsule taken orally with (preferred) or without food, 252 mg twice daily, 28 days for a cycle.
干预措施: TL118 Capsule (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Pre-dose up to approximately 24 months post-dose
次要结局
- Maximum Plasma Concentration (Cmax) of TL118(Pre-dose up to 12 hours post-dose)
- TL118 half-life (T1/2)(Pre-dose up to 12 hours post-dose)
- Time to Peak Drug Concentration (Tmax) of TL118(Pre-dose up to 12 hours post-dose)
- Apparent Clearance (CL/f) of TL118(Pre-dose up to 12 hours post-dose)
- Disease Control Rate (DCR)(Pre-dose up to approximately 24 months post-dose)
- Progression Free Survival (PFS)(Pre-dose up to approximately 24 months post-dose)
- Time to Tumor Progression (TTP)(Pre-dose up to approximately 24 months post-dose)
- Time to Treatment Failure (TTF)(Pre-dose up to approximately 24 months post-dose)
- Overall Survival (OS)(Pre-dose up to approximately 24 months post-dose)
- Area Under The Curve (AUC) of TL118(Pre-dose up to 12 hours post-dose)
- Volume of Distribution (Vz/F) of TL118(Pre-dose up to 12 hours post-dose)
- Time to Response (TTR)(Pre-dose up to approximately 24 months post-dose)
- 1-year Survival(Pre-dose up to approximately 24 months post-dose)
- Number of Participants Experiencing Serious Adverse Events (SAE)(Pre-dose up to approximately 24 months post-dose)
- Number of Participants Experiencing Serious Adverse Reactions (SAR)(Pre-dose up to approximately 24 months post-dose)
- 1-year Progression Free Survival(Pre-dose up to approximately 24 months post-dose)
- Number of Participants Experiencing Adverse Events (AE)(Pre-dose up to approximately 24 months post-dose)
- Number of Participants Experiencing Adverse Drug Reactions (ADR)(Pre-dose up to approximately 24 months post-dose)
- Duration of Response (DoR)(Pre-dose up to approximately 24 months post-dose)
- Minimum Plasma Concentration (Cmin) of TL118(Pre-dose up to 12 hours post-dose)
研究者
研究点 (38)
Loading locations...
相似试验
Unknown
2 期
Investigator's Initiated Phase II Study for Pancreatic Cancer PatientsPancreatic CancerNCT01659502Tiltan Pharma Ltd.10
招募中
1 期
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)Lymphoblastic LeukemiaLymphoblastic LymphomaAcute LeukemiaNCT06207123University of Chicago15
撤回
2 期
Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat InfluenzaInfluenzaNCT03903718MedImmune LLC
已完成
2 期
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic LeukemiaLymphocyticChronicLeukemiaNCT00077922National Cancer Institute (NCI)15
已完成
1 期
Thorough QT (TQT) Study of TD-4208 in Healthy SubjectsCardiac Repolarization in Healthy SubjectsNCT02820311Mylan Inc.48